Neutropenia

• CLINICAL_TRIALS research · 2010-08-04
  Clinical Trial Update: Maintaining a Higher Level of Haemoglobin: Effect on the White Cells After Bone Marrow Transplantation in Children. [Phase 2]

  A Phase 2 pediatric trial assessing whether maintaining higher haemoglobin levels affects white blood cell recovery after bone marrow transp…

• FDA approval · 2010-03-02
  FDA Approved: NEUPOGEN — Supplemental Application (Amgen, Inc)

  FDA approved a supplemental application for NEUPOGEN (filgrastim) from Amgen, Inc.

• CLINICAL_TRIALS trial_result · 2008-10-21
  Clinical Trial Update: Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17 [Phase 1, Phase 2]

  Pfizer-conducted Phase 1/2 trial in immunocompromised children (ages 2-17) assessed safety, tolerance, and pharmacokinetics of the antifunga…

• CLINICAL_TRIALS research · 2008-07-24
  Clinical Trial Update: Therapeutic Drug Monitoring (TDM) of Voriconazole and Correlation With CYP2C19 Genotype in Korean Populations

  This clinical trial update examines therapeutic drug monitoring of voriconazole and its correlation with CYP2C19 genotype in Korean populati…

• FDA approval · 2008-04-16
  FDA Approved: NEULASTA — Supplemental Application (Amgen, Inc)

  The FDA approved a supplemental application for NEULASTA (pegfilgrastim) by Amgen, Inc., approving changes to the drug’s labeling and/or ind…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2008-03-04
  Clinical Trial Update: Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia [Phase 1]

  Phase I study evaluating the safety, tolerability, and pharmacokinetics of FK463 in immunocompromised children with fever and neutropenia; t…

• CLINICAL_TRIALS research · 2007-11-08
  Clinical Trial Update: A Pilot Study to Evaluate the Safety and Activities of EW02 in Reducing Neutropenia Caused by Chemotherapy [Phase 1, Phase 2]

  This is an update on a Phase 1/2 pilot trial evaluating EW02 for safety and its ability to reduce chemotherapy-induced neutropenia in breast…

• CLINICAL_TRIALS trial_result · 2007-08-30
  Clinical Trial Update: Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia [Phase 2]

  Phase 2 trial evaluating Mannan-binding lectin substitution in MBL-deficient children with chemotherapy-induced neutropenia has been complet…

• FDA approval · 2007-07-23
  FDA Approved: NEULASTA — Supplemental Application (Amgen, Inc)

  FDA approved a supplemental application for NEULASTA (pegfilgrastim) from Amgen, authorizing changes to the existing labeling.

• FDA approval · 2006-10-25
  FDA Approved: NEUPOGEN — Supplemental Application (Amgen, Inc)

  FDA approved a supplemental application for NEUPOGEN (filgrastim) submitted by Amgen, Inc. The action relates to the approval of changes in …

• FDA approval · 2006-10-25
  FDA Approved: NEULASTA — Supplemental Application (Amgen, Inc)

  The FDA approved a supplemental application for NEULASTA (pegfilgrastim) submitted by Amgen.